Russia is advancing multiple experimental cancer immunotherapy approaches, including the oncolytic vaccine Enteromix (also referred to as EnteroMix) and personalized treatments such as the mRNA-based Neooncovac (or NeoOncoVac) and the peptide-based Oncopept.
As of early April 2026, these initiatives are moving from preclinical and early clinical stages toward broader testing and potential integration into the national healthcare system.
Enteromix: Oncolytic virus-based approach
Enteromix, developed by the National Medical Research Radiological Center (NMRRC) of the Ministry of Health in collaboration with the Engelhardt Institute of Molecular Biology, uses a combination of non-pathogenic viruses. These are engineered to selectively infect and destroy cancer cells while triggering a broader antitumor immune response.
Preclinical studies have reported effects ranging from slowed tumor growth to complete tumor elimination in animal models, with repeated dosing described as safe. Russian officials, including those from the Federal Medical-Biological Agency, have highlighted strong immune activation and tumor reduction, particularly in colorectal cancer models, sometimes citing high efficacy rates in controlled settings.
Phase I clinical trials for Enteromix began enrolling volunteers around late 2025 or early 2026, with expansion planned to other indications such as glioblastoma and melanoma. While domestic reports express optimism, independent international experts emphasize that these early results come from limited cohorts and require larger, peer-reviewed Phase II and III trials to confirm safety, long-term effectiveness, and applicability across diverse patient groups.
Some coverage has described the vaccine as ‘ready for clinical use’ following preclinical success, though full regulatory approval processes continue.
Personalized mRNA and Peptide vaccines: Neooncovac and Oncopept
Parallel efforts focus on individualized therapies.
Neooncovac is an mRNA-based personalized vaccine, drawing on technology platforms refined during COVID-19 vaccine development (including work at the Gamaleya National Research Center). It analyzes a patient’s tumor genetics to identify unique neoantigens, then produces a custom formulation to train the immune system to target those specific cancer markers.
Preclinical animal studies have shown signs of tumor regression and reduced metastasis in models such as advanced melanoma. Early human experimental use or Phase I trials have targeted melanoma, with potential expansion to other cancers like pancreatic, kidney, and lung.
Oncopept is a peptide-based personalized vaccine designed to address aggressive tumors, notably colorectal cancers. It uses short protein fragments to stimulate immune recognition of tumor-specific antigens. Both personalized approaches benefit from AI-assisted tools that speed up mutation profiling and vaccine design, shortening the timeline from tumor sampling to treatment readiness.
Development involves collaboration among NMRRC, Gamaleya, the Blokhin National Medical Research Center of Oncology, and other institutions.
Policy milestone: Insurance coverage proposal
A key development came in March 2026 when Russia’s Ministry of Health proposed incorporating personalized mRNA vaccines (including Neooncovac), the peptide vaccine Oncopept, and related cell-based immunotherapies into the compulsory medical insurance program. This would cover high-tech antitumor therapies lasting more than six months, with adjusted funding standards to reflect the complex, patient-specific manufacturing process.
If approved, these treatments could become accessible at no direct cost to eligible patients later in 2026, building on earlier government commitments to provide advanced oncology care through the public system.
Complementary traditional care and challenges
Alongside these innovations, authorities continue to strengthen conventional treatments. In early 2026, the Ministry of Health instructed domestic producers (such as Promomed and Biocad) to increase the output of essential chemotherapy drugs like carboplatin to address regional shortages.
Experts note that while mRNA and oncolytic platforms build on proven technologies, significant hurdles remain, such as the high production costs and time requirements for personalization, the need for robust large-scale clinical data, and limited independent international verification of results so far.
Global oncology researchers view these efforts as part of a broader, promising field of personalized cancer immunotherapy, with similar work underway in the United States, Europe, and elsewhere.
Russian officials express confidence that these ‘new-generation’ therapies could eventually complement or reduce reliance on traditional treatments for certain patients. Ongoing trials, potential insurance integration, and international interest (including reported discussions with partners like Serbia) could determine the pace of progress.